Webinar : Radioimmunoconjugates for Theranostic Applications
Radioimmunoconjugates for Theranostic Applications
Prof. Franck Denat | ICMUB (CNRS)
From Molecular Imaging to Targeted Therapy
How can radiopharmaceuticals be designed to image disease and deliver targeted radiation to tumors?
Discover how radiotheranostics connects molecular imaging with targeted cancer treatment.
About the Webinar
Prof. Franck Denat explores the design of radioimmunoconjugates and explains how radionuclides, chelators, linkers, and bioconjugation strategies influence stability, biodistribution, tumor uptake, and therapeutic efficacy.
The presentation examines imaging radionuclides such as gallium-68 and zirconium-89, alongside therapeutic isotopes including lutetium-177 and actinium-225.
Through clinical examples such as Lutathera and Pluvicto, the webinar illustrates how molecular imaging can guide patient selection and targeted treatment. It also explores alpha and beta therapy, site-specific conjugation, pretargeting, multimodal imaging, and challenges in radiopharmaceutical development.
Key Topics Covered
Radiotheranostics
Molecular imaging and targeted radionuclide therapy.
Radionuclides & Chelators
Selection, stability, and radiopharmaceutical design.
Bioconjugation Strategies
Site-specific conjugation and pretargeting approaches.
Targeted Therapies
Alpha and beta therapy in precision oncology.
Multimodal Imaging
Fluorescence-guided surgery and combined imaging.
Clinical Translation
Scientific, regulatory, and logistical challenges.